Skip to main content
    G

    GT Biopharma Inc (GTBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.54
    -0.18 (-4.97%)

    Market Cap: $7.67M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    GT Biopharma Inc (GTBP) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    GT Biopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$28.35M, operating cash flow was -$12.91M and free cash flow was -$12.91M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$4.52M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $12.42M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$3.47M$5.80M$6.47M$8.81M$9.59M$485.00K-$1.67M$9.07M$1.07M$975.00K
    Operating income-$12.42M-$14.36M-$13.58M-$21.26M-$57.52M-$6.76M$16.06M-$250.07M-$135.57M-$9.37M
    Net income-$28.35M-$13.16M-$7.60M-$20.88M-$58.01M-$28.30M-$38.65M-$518.37M-$144.17M$19.54M
    EBITDAN/A-$13.56M-$8.71M-$21.17M-$57.33MN/A$37.03MN/A-$128.46M$30.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating income-$4.51M-$2.85M-$5.59M-$3.38M-$1.51M-$1.93M-$3.76M-$3.60M-$3.91M-$3.09M-$3.17M-$3.12M
    Net income-$4.52M-$2.83M-$23.03M$8.30M-$30.17M-$776.00K-$3.77M-$3.41M-$3.71M-$2.27M-$2.96M-$2.42M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $6.81M were 84.0% of total assets of $8.11M, against total liabilities of $2.32M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$8.11M$4.23M$14.11M$16.74M$32.17M$5.66M$396.00K$25.40M$254.37M$25.00K
    Current assets$8.11M$4.23M$14.06M$16.56M$32.17M$5.66M$274.00K$90.00K$576.00K$21.00K
    Cash and equivalents$6.81M$3.95M$1.08M$5.67M$8.97M$5.30M$28.00K$60.00K$576.00K$19.00K
    Total liabilities$2.32M$5.90M$6.63M$5.00M$10.26M$35.09M$19.71M$14.03M$2.68M$18.95M
    Short-term debtN/AN/A$58.00K$110.00K$31.00K$26.30M$13.21M$10.77M$0$11.24M
    Shareholder equity$5.79M-$1.67M$7.48M$11.73M$21.91M-$29.43M-$19.14M$11.54M$251.86M-$18.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$5.79M$10.00M$8.11M$4.32M$7.12M$2.66M$4.23M$6.76M$9.27M$9.91M$14.11M$16.15M
    Total liabilities$2.22M$2.42M$2.32M$1.32M$31.04M$3.64M$5.90M$4.66M$3.76M$4.60M$6.63M$6.14M
    Cash and equivalents$4.96M$8.92M$6.81M$2.53M$5.23M$2.37M$3.95M$6.42M$9.25M$1.95M$1.08M$2.65M
    Shareholder equity$3.57M$7.58M$5.79M$3.00M-$25.88M-$980.00K-$1.67M$2.10M$5.51M$5.31M$7.48M$10.01M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$12.91M-$12.90M-$8.85M-$15.22M-$15.61M-$7.26M-$3.66M-$10.68M-$5.43M-$1.93M
    Capital expenditures$0$0$0$0$0$0$0$36.00K$4.00K$0
    Free cash flow-$12.91M-$12.90M-$8.85M-$15.22M-$15.61M-$7.26M-$3.66M-$10.71M-$5.43M-$1.93M
    Dividends paid$229.00K$0N/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$0$12.89M-$2.01M$12.14M-$23.04M$0$200.00K-$36.00K-$4.00K$0
    Financing cash flow$15.78M$2.98M$6.27M-$224.00K$42.32M$12.53M$3.43M$10.20M$5.99M$1.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$4.26M-$2.47M-$4.02M-$3.68M-$3.01M-$2.20M-$2.47M-$2.74M-$3.54M-$4.16M-$2.05M-$1.96M
    Free cash flowN/A-$2.47M-$4.02M-$3.68M-$3.01M-$2.20M-$2.47M-$2.74M-$3.54M-$4.16M-$2.05M-$1.96M
    Last 12 quarters

    Frequently Asked Questions About GTBP

    What is GT Biopharma's annual revenue?

    GT Biopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is GT Biopharma profitable?

    No. GT Biopharma reported net income of -$28.35M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GTBP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.91M minus capital expenditures of $0 produced free cash flow of -$12.91M.

    How much debt does GT Biopharma have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $6.81M.